FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214340074> ?p ?o ?g. }

• W3214340074 endingPage "1565" @default.
• W3214340074 startingPage "1565" @default.
• W3214340074 abstract "Abstract Introduction: The transformation of chronic lymphocytic leukemia (CLL) into a highly aggressive B-cell lymphoma histology, known as Richter's syndrome (RS), is associated with rapid progression and remains a serious treatment challenge. Standard chemoimmunotherapy approaches often yield poor response rates, short remission durations, and limited overall survival. The role of radiation therapy (RT) in the management of RS has not been explored, and decision making regarding the use of RT in RS is extrapolated from the de novo diffuse large B cell lymphoma (DLBCL) literature. Herein, we report, to the best of our knowledge, the largest case series of patients with RS who received RT. Methods: We conducted a retrospective review of all patients Memorial Sloan Kettering Cancer Center diagnosed with DLBCL RS between April 2002 and August 2020 who received RT at any time following RS diagnosis. Baseline characteristics, information regarding CLL- and RS-directed therapy, RT characteristics including its therapeutic intent, and outcomes were collected. Progression free and overall survival (PFS, OS) were estimated using Kaplan Meier method. All other analyses were descriptive. Analyses were performed using STATA 17.0. Results: 34 RS patients who received RT were identified. Twenty-one received RT as part of a definitive therapeutic strategy while 13 received RT solely for palliation. Baseline characteristics for the entire cohort, as well as divided by RT therapeutic intent, are described in Table 1. Patients received a median of 1 (range 0-5) prior line of CLL-directed therapy prior to RS diagnosis; 24% had prior ibrutinib while 9% had prior venetoclax. Patients received a median of 2 (range 0-5) lines of RS-directed therapy prior to RT; chemoimmunotherapy was first-line RS-directed therapy for 82%. Figure 1 depicts a swimmer's plot for all patients from time of RS diagnosis and includes timing of RT and cellular therapy (CAR-T or allogeneic stem cell transplant, alloSCT). Heterogeneity in the parameters of radiation utilized reflected diverse clinical situations in this cohort. Across the cohort, most commonly irradiated areas included head and neck sites (n=11), abdomen (n=5), paraspinal (n=4) and pelvis/groin (n=4). Median delivered dose was 30.6 Gy (range: 18-54) and 25 Gy (range: 4.5-45) for the definitively and palliatively-treated patients, respectively. Four patients (3 palliative, 1 consolidative) did not complete prescribed course of RT. We subsequently focused on 21 patients treated with RT as part of a definitive therapeutic strategy. With a median follow-up time of 5.8 (range 0.2 - 18.5) years, median OS was estimated to be 6.8 years from RS diagnosis. Fourteen patients (67%) experienced DLBCL progression following RT. A subset of 12 patients received RT following chemoimmunotherapy without immediate cellular therapy in the front-line setting (58%; 7/12) or relapsed/refractory setting (42%; 5/12). Response at the time of RT was CR/clinical CR in 7 patients (58%), PR in 3 (25%), and PD in 1 (8%); response at the time of RT was unknown for 1 patient. In this subset, four (33%) experienced RS disease relapse with 2 occurring within the prior radiation field and 2 occurring distantly. Two patients received RT as an up-front therapy prior to any chemoimmunotherapy in the setting of localized disease. One of these two subsequently had a DLBCL relapse within the prior radiation field. RT was used as a bridging strategy to cellular therapy in 7 patients including alloSCT (n=4) and CAR-T (n=3). Four patients experienced RS relapse. Estimated median PFS was 1.1 years and median OS was 1.9 years from time of cellular therapy. Conclusion: In the largest single-institution series to describe the use of RT in RS, patients who received RT for the diagnosis of RS experienced favorable long-term survival when used as part of a definitive therapeutic strategy, including consolidation following chemoimmunotherapy and as bridging to cellular therapy. These data suggest a role for RT in the management of RS to be further explored through multicenter collaborations and prospective studies. Figure 1 Figure 1. Disclosures Thompson: VJHemOnc: Honoraria; Curio Science: Honoraria; MJH Life Sciences: Honoraria. Mato: Acerta/AstraZeneca: Consultancy, Research Funding; LOXO: Consultancy, Research Funding; Nurix: Research Funding; Sunesis: Consultancy, Research Funding; Adaptive Biotechnologies: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Pharmacyclics LLC, an AbbVie Company: Consultancy, Research Funding; Genmab: Research Funding; AstraZeneca: Consultancy; DTRM BioPharma: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Johnson and Johnson: Consultancy, Research Funding; TG Therapeutics: Consultancy, Other: DSMB, Research Funding; MSKCC: Current Employment. Roeker: AbbVie, AstraZeneca, Janssen, LOXO, Pharmacyclics, TG Therapeutics, Vaniam Group, Verastem: Consultancy; Pfizer: Consultancy, Research Funding; Pharmacyclics: Consultancy; TG Therapeutics: Consultancy; Loxo Oncology: Consultancy; Abbot Laboratories: Current equity holder in publicly-traded company." @default.
• W3214340074 created "2021-11-22" @default.
• W3214340074 creator A5006316893 @default.
• W3214340074 creator A5007588773 @default.
• W3214340074 creator A5023759382 @default.
• W3214340074 creator A5042723532 @default.
• W3214340074 creator A5066521233 @default.
• W3214340074 creator A5074971164 @default.
• W3214340074 creator A5083072418 @default.
• W3214340074 date "2021-11-05" @default.
• W3214340074 modified "2023-09-30" @default.
• W3214340074 title "Radiation Therapy for Patients with Diffuse Large B Cell Richter's Syndrome of CLL" @default.
• W3214340074 doi "https://doi.org/10.1182/blood-2021-153771" @default.
• W3214340074 hasPublicationYear "2021" @default.
• W3214340074 type Work @default.
• W3214340074 sameAs 3214340074 @default.
• W3214340074 citedByCount "0" @default.
• W3214340074 crossrefType "journal-article" @default.
• W3214340074 hasAuthorship W3214340074A5006316893 @default.
• W3214340074 hasAuthorship W3214340074A5007588773 @default.
• W3214340074 hasAuthorship W3214340074A5023759382 @default.
• W3214340074 hasAuthorship W3214340074A5042723532 @default.
• W3214340074 hasAuthorship W3214340074A5066521233 @default.
• W3214340074 hasAuthorship W3214340074A5074971164 @default.
• W3214340074 hasAuthorship W3214340074A5083072418 @default.
• W3214340074 hasBestOaLocation W32143400741 @default.
• W3214340074 hasConcept C121608353 @default.
• W3214340074 hasConcept C126322002 @default.
• W3214340074 hasConcept C143998085 @default.
• W3214340074 hasConcept C167135981 @default.
• W3214340074 hasConcept C2776694085 @default.
• W3214340074 hasConcept C2777938653 @default.
• W3214340074 hasConcept C2778461978 @default.
• W3214340074 hasConcept C2778559949 @default.
• W3214340074 hasConcept C2779338263 @default.
• W3214340074 hasConcept C2779878957 @default.
• W3214340074 hasConcept C2780653079 @default.
• W3214340074 hasConcept C2780739268 @default.
• W3214340074 hasConcept C2780790343 @default.
• W3214340074 hasConcept C509974204 @default.
• W3214340074 hasConcept C71924100 @default.
• W3214340074 hasConcept C72563966 @default.
• W3214340074 hasConceptScore W3214340074C121608353 @default.
• W3214340074 hasConceptScore W3214340074C126322002 @default.
• W3214340074 hasConceptScore W3214340074C143998085 @default.
• W3214340074 hasConceptScore W3214340074C167135981 @default.
• W3214340074 hasConceptScore W3214340074C2776694085 @default.
• W3214340074 hasConceptScore W3214340074C2777938653 @default.
• W3214340074 hasConceptScore W3214340074C2778461978 @default.
• W3214340074 hasConceptScore W3214340074C2778559949 @default.
• W3214340074 hasConceptScore W3214340074C2779338263 @default.
• W3214340074 hasConceptScore W3214340074C2779878957 @default.
• W3214340074 hasConceptScore W3214340074C2780653079 @default.
• W3214340074 hasConceptScore W3214340074C2780739268 @default.
• W3214340074 hasConceptScore W3214340074C2780790343 @default.
• W3214340074 hasConceptScore W3214340074C509974204 @default.
• W3214340074 hasConceptScore W3214340074C71924100 @default.
• W3214340074 hasConceptScore W3214340074C72563966 @default.
• W3214340074 hasIssue "Supplement 1" @default.
• W3214340074 hasLocation W32143400741 @default.
• W3214340074 hasOpenAccess W3214340074 @default.
• W3214340074 hasPrimaryLocation W32143400741 @default.
• W3214340074 hasRelatedWork W1550739321 @default.
• W3214340074 hasRelatedWork W2106082064 @default.
• W3214340074 hasRelatedWork W2256822827 @default.
• W3214340074 hasRelatedWork W2294347960 @default.
• W3214340074 hasRelatedWork W2900467419 @default.
• W3214340074 hasRelatedWork W2902300122 @default.
• W3214340074 hasRelatedWork W2905243278 @default.
• W3214340074 hasRelatedWork W2966190920 @default.
• W3214340074 hasRelatedWork W3086386184 @default.
• W3214340074 hasRelatedWork W2912615048 @default.
• W3214340074 hasVolume "138" @default.
• W3214340074 isParatext "false" @default.
• W3214340074 isRetracted "false" @default.
• W3214340074 magId "3214340074" @default.
• W3214340074 workType "article" @default.